Skip to content
Disclosery

BML Capital Management, LLC

Follow

13F filer, CIK 1616824, ZIONSVILLE, IN

BML Capital Management, LLC reported $123,560,622 across 27 holdings for the quarter ended 2025-03-31, in a 13F-HR filed 2025-05-07. Its ten largest share positions make up 86.46% of the portfolio.

Filed (acceptance time not in the bulk data set), ingested 13F-HR 0001754960-25-000280

Period
2025-03-31
Reported value
$124M
Holdings
27
Top 10 weight
86.46%
New
6
Sold out
4

Largest buys vs the previous quarter

SecurityShares changeApprox. value
THRDnew+3,824,417$13.3M
LAVA THERAPEUTICS NVnew+1,960,610$2.49M
ADVERUM BIOTECHNOLOGIES INCadded+474,253$2.07M
KZRadded+359,470$1.75M
ELEVATION ONCOLOGY INC COMnew+5,890,934$1.53M

Ranked by the share change valued at this quarter's implied price (value over shares in the 13F). A position sold out is valued at the previous quarter's price, its last report.

Largest sells vs the previous quarter

SecurityShares changeApprox. value
SGOVexited-260,000-$26.1M
PVLAexited-42,130-$506K
WHWKreduced-209,755-$373K
LENZexited-9,271-$268K
LSTAreduced-67,816-$159K

Ranked by the share change valued at this quarter's implied price (value over shares in the 13F). A position sold out is valued at the previous quarter's price, its last report.

Holdings, Q1 2025

Share positions as resolved from 13F-HR 0001754960-25-000280, largest first. % of portfolio is the value over $123,560,622, the sum of the share positions whose value is usable for ratios (method).

SecurityHistorySharesValue% of portfolioChangeLatest eventTimeline
AVIRATEA PHARMACEUTICALS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2023Q2: restricted; 2023Q3: restricted; 2023Q4: restricted; 2024Q1: restricted; 2024Q2: restricted; 2024Q3: 6,650,000 shares; 2024Q4: 7,608,312 shares; 2025Q1: 7,609,812 shares 7,609,812$22.8M18.41%+1,500Timeline
ACRSACLARIS THERAPEUTICS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2023Q2: restricted; 2023Q3: restricted; 2023Q4: restricted; 2024Q1: restricted; 2024Q2: restricted; 2024Q3: 14,250,000 shares; 2024Q4: 14,250,000 shares; 2025Q1: 14,250,000 shares 14,250,000$21.8M17.65%0Timeline
THRDTHIRD HARMONIC BIO INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2023Q2: restricted; 2023Q3: restricted; 2023Q4: restricted; 2024Q1: restricted; 2024Q2: restricted; 2024Q3: not reported; 2024Q4: not reported; 2025Q1: 3,824,417 shares 3,824,417$13.3M10.74%newTimeline
ADVERUM BIOTECHNOLOGIES INCADVERUM BIOTECHNOLOGIES INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2023Q2: restricted; 2023Q3: restricted; 2023Q4: restricted; 2024Q1: restricted; 2024Q2: restricted; 2024Q3: 2,268,064 shares; 2024Q4: 2,268,064 shares; 2025Q1: 2,742,317 shares 2,742,317$12M9.7%+474,253
ANTXAN2 THERAPEUTICS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2023Q2: restricted; 2023Q3: restricted; 2023Q4: restricted; 2024Q1: restricted; 2024Q2: restricted; 2024Q3: 5,749,432 shares; 2024Q4: 5,749,432 shares; 2025Q1: 5,749,432 shares 5,749,432$7.82M6.33%0Timeline
TILINSTIL BIO INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2023Q2: restricted; 2023Q3: restricted; 2023Q4: restricted; 2024Q1: restricted; 2024Q2: restricted; 2024Q3: 335,000 shares; 2024Q4: 400,000 shares; 2025Q1: 416,720 shares 416,720$7.23M5.85%+16,720Timeline
ESSA PHARMA INCESSA PHARMA INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2023Q2: restricted; 2023Q3: restricted; 2023Q4: restricted; 2024Q1: restricted; 2024Q2: restricted; 2024Q3: not reported; 2024Q4: 4,221,546 shares; 2025Q1: 4,221,546 shares 4,221,546$6.67M5.4%0
ORMPORAMED PHARMACEUTICALS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2023Q2: restricted; 2023Q3: restricted; 2023Q4: restricted; 2024Q1: restricted; 2024Q2: restricted; 2024Q3: 2,186,191 shares; 2024Q4: 2,643,907 shares; 2025Q1: 3,020,748 shares 3,020,748$6.46M5.23%+376,841Timeline
IKENA ONCOLOGY INCIKENA ONCOLOGY INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2023Q2: restricted; 2023Q3: restricted; 2023Q4: restricted; 2024Q1: restricted; 2024Q2: restricted; 2024Q3: 723,288 shares; 2024Q4: 3,585,866 shares; 2025Q1: 3,710,803 shares 3,710,803$4.75M3.84%+124,937
PMVPPMV PHARMACEUTICALS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2023Q2: restricted; 2023Q3: restricted; 2023Q4: restricted; 2024Q1: restricted; 2024Q2: restricted; 2024Q3: 1,688,772 shares; 2024Q4: 3,466,684 shares; 2025Q1: 3,747,612 shares 3,747,612$4.08M3.31%+280,928Timeline
WHWKWHITEHAWK THERAPEUTICS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2023Q2: restricted; 2023Q3: restricted; 2023Q4: restricted; 2024Q1: restricted; 2024Q2: restricted; 2024Q3: 2,000,000 shares; 2024Q4: 2,100,000 shares; 2025Q1: 1,890,245 shares 1,890,245$3.36M2.72%-209,755Timeline
LAVA THERAPEUTICS NVLAVA THERAPEUTICS NVQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2023Q2: restricted; 2023Q3: restricted; 2023Q4: restricted; 2024Q1: restricted; 2024Q2: restricted; 2024Q3: not reported; 2024Q4: not reported; 2025Q1: 1,960,610 shares 1,960,610$2.49M2.02%new
KZRKEZAR LIFE SCIENCES INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2023Q2: restricted; 2023Q3: restricted; 2023Q4: restricted; 2024Q1: restricted; 2024Q2: restricted; 2024Q3: not reported; 2024Q4: 48,668 shares; 2025Q1: 408,138 shares 408,138$1.99M1.61%+359,470Timeline
ELEVATION ONCOLOGY INC COMELEVATION ONCOLOGY INC COMQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2023Q2: restricted; 2023Q3: restricted; 2023Q4: restricted; 2024Q1: restricted; 2024Q2: restricted; 2024Q3: not reported; 2024Q4: not reported; 2025Q1: 5,890,934 shares 5,890,934$1.53M1.24%new
ASTCASTROTECH CORPQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2023Q2: restricted; 2023Q3: restricted; 2023Q4: restricted; 2024Q1: restricted; 2024Q2: restricted; 2024Q3: 220,410 shares; 2024Q4: 220,410 shares; 2025Q1: 220,410 shares 220,410$1.43M1.16%0Timeline
CONNECT BIOPHARMA HLDGS LTDCONNECT BIOPHARMA HLDGS LTDQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2023Q2: restricted; 2023Q3: restricted; 2023Q4: restricted; 2024Q1: restricted; 2024Q2: restricted; 2024Q3: 2,093,232 shares; 2024Q4: 2,093,232 shares; 2025Q1: 2,093,232 shares 2,093,232$1.15M0.93%0
SAGE THERAPEUTICS INCSAGE THERAPEUTICS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2023Q2: restricted; 2023Q3: restricted; 2023Q4: restricted; 2024Q1: restricted; 2024Q2: restricted; 2024Q3: not reported; 2024Q4: not reported; 2025Q1: 135,095 shares 135,095$1.07M0.87%new
ATHIRA PHARMA INCATHIRA PHARMA INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2023Q2: restricted; 2023Q3: restricted; 2023Q4: restricted; 2024Q1: restricted; 2024Q2: restricted; 2024Q3: not reported; 2024Q4: 2,775,885 shares; 2025Q1: 3,200,667 shares 3,200,667$912K0.74%+424,782
MISTMILESTONE PHARMACEUTICALS INQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2023Q2: restricted; 2023Q3: restricted; 2023Q4: restricted; 2024Q1: restricted; 2024Q2: restricted; 2024Q3: 1,136,091 shares; 2024Q4: 1,136,091 shares; 2025Q1: 1,136,091 shares 1,136,091$909K0.74%0Timeline
LSTALISATA THERAPEUTICS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2023Q2: restricted; 2023Q3: restricted; 2023Q4: restricted; 2024Q1: restricted; 2024Q2: restricted; 2024Q3: 284,669 shares; 2024Q4: 284,669 shares; 2025Q1: 216,853 shares 216,853$510K0.41%-67,816Timeline
TURNSTONE BIOLOGICS CORPTURNSTONE BIOLOGICS CORPQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2023Q2: restricted; 2023Q3: restricted; 2023Q4: restricted; 2024Q1: restricted; 2024Q2: restricted; 2024Q3: not reported; 2024Q4: not reported; 2025Q1: 1,103,386 shares 1,103,386$452K0.37%new
VTGNVISTAGEN THERAPEUTICS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2023Q2: restricted; 2023Q3: restricted; 2023Q4: restricted; 2024Q1: restricted; 2024Q2: restricted; 2024Q3: 150,000 shares; 2024Q4: 150,000 shares; 2025Q1: 150,000 shares 150,000$375K0.3%0Timeline
ALMSALUMIS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2023Q2: restricted; 2023Q3: restricted; 2023Q4: restricted; 2024Q1: restricted; 2024Q2: restricted; 2024Q3: not reported; 2024Q4: not reported; 2025Q1: 49,627 shares 49,627$305K0.25%newTimeline
NEXTCURE INCNEXTCURE INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2023Q2: restricted; 2023Q3: restricted; 2023Q4: restricted; 2024Q1: restricted; 2024Q2: restricted; 2024Q3: 276,465 shares; 2024Q4: 273,536 shares; 2025Q1: 273,536 shares 273,536$131K0.11%0
VERRICA PHARMACEUTICALS INCVERRICA PHARMACEUTICALS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2023Q2: restricted; 2023Q3: restricted; 2023Q4: restricted; 2024Q1: restricted; 2024Q2: restricted; 2024Q3: 180,000 shares; 2024Q4: 174,651 shares; 2025Q1: 174,651 shares 174,651$77.2K0.06%0
HILLEVAX INCHILLEVAX INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2023Q2: restricted; 2023Q3: restricted; 2023Q4: restricted; 2024Q1: restricted; 2024Q2: restricted; 2024Q3: 19,760 shares; 2024Q4: 20,760 shares; 2025Q1: 20,760 shares 20,760$30.1K0.02%0
ACHILLES THERAPEUTICS PL-ADRACHILLES THERAPEUTICS PL-ADRQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2023Q2: restricted; 2023Q3: restricted; 2023Q4: restricted; 2024Q1: restricted; 2024Q2: restricted; 2024Q3: 4,100,002 shares; 2024Q4: 4,100,002 shares; 2025Q1: 3,804,921 shares 3,804,921$00%-295,081Value filed as zero, left out of ratios.

Sold out in Q1 2025

Positions in the previous quarter's report that this quarter's report no longer lists.

SecurityShares beforeValue beforeType
SGOVISHARES TR260,000$26.1Mshares
PVLAPALVELLA THERAPEUTICS INC NE42,130$506Kshares
LENZLENZ THERAPEUTICS INC9,271$268Kshares
ALLOVIR INCALLOVIR INC184,246$77.4Kshares

How Q1 2025 was built

Available 13F filings of this filer for the quarter and their roles: the base report is the latest original or restatement, NEW HOLDINGS amendments filed after it are added (method).

FilingRoleAmendmentFiledAcceptedIngested
13F-HR 0001754960-25-000280 base2025-05-07acceptance time not in the bulk data set